The modulation of cellular processes by small molecule inhibitors, gene inactivation or targeted knock-down strategies combined with phenotypic screens are powerful approaches to delineate complex cellular pathways and to identify key players involved in disease pathogenesis. Using chemical genetic screening, we tested a library of known phosphatase inhibitors and identified several compounds that protected Bacillus anthracis infected macrophages from cell death. The most potent compound was assayed against a panel of sixteen different phosphatases of which CD45 was found to be most sensitive to inhibition. Testing of a known CD45 inhibitor and antisense phosphorodiamidate morpholino oligomers targeting CD45 also protected B. anthracis infected macrophages from cell death. However, reduced CD45 expression did not protect anthrax lethal toxin (LT) treated macrophages, suggesting that the pathogen and independently added LT may signal through distinct pathways. Subsequent, in vivo studies with both gene targeted knock-down of CD45 and genetically engineered mice expressing reduced levels of CD45 resulted in protection of mice following infection with the virulent Ames B. anthracis. Intermediate levels of CD45 expression were critical for the protection, as mice expressing normal levels of CD45 or disrupted CD45 phosphatase activity or no CD45, all succumbed to this pathogen. Mechanism-based studies suggest that the protection provided by reduced CD45 levels results from regulated immune cell homeostasis that may diminish the impact of apoptosis during the infection. To date, this is the first report demonstrating that reduced levels of host phosphatase CD45 modulate anthrax pathogenesis.
The modulation of cellular processes by small molecule inhibitors, gene inactivation or targeted knock-down strategies combined with phenotypic screens are powerful approaches to delineate complex cellular pathways and to identify key players involved in disease pathogenesis. Using chemical genetic screening, we tested a library of known phosphatase inhibitors and identified several compounds that protected Bacillus anthracis infected macrophages from cell death. The most potent compound was assayed against a panel of sixteen different phosphatases of which CD45 was found to be most sensitive to inhibition. Testing of a known CD45 inhibitor and antisense phosphorodiamidate morpholino oligomers targeting CD45 also protected B. anthracis infected macrophages from cell death. However, reduced CD45 expression did not protect anthrax lethal toxin (LT) treated macrophages, suggesting that the pathogen and independently added LT may signal through distinct pathways. Subsequent, in vivo studies with both gene targeted knock-down of CD45 and genetically engineered mice expressing reduced levels of CD45 resulted in protection of mice following infection with the virulent Ames B. anthracis. Intermediate levels of CD45 expression were critical for the protection, as mice expressing normal levels of CD45 or disrupted CD45 phosphatase activity or no CD45, all succumbed to this pathogen. Mechanism-based studies suggest that the protection provided by reduced CD45 levels results from regulated immune cell homeostasis that may diminish the impact of apoptosis during the infection. To date, this is the first report demonstrating that reduced levels of host phosphatase CD45 modulate anthrax pathogenesis.
Interactions between microbes and immune cells play a critical role in microbial pathogenesis. Many pathogenic organisms exploit the host's immune machinery and subsequently modulate cell function, signaling, migration and cytoskeleton rearrangement. Hence, identifying host cellular components with which microbes interact will allow for a more comprehensive understanding of microbial pathogenesis, define common strategies used by multiple pathogens and elucidate unique tactics evolved by individual species to help establish infections or evade host innate responses. Another interesting aspect of infection is that diverse pathogens seem to target common cellular pathways (1, 2) .
Thus, identifying host targets exploited by multiple pathogens will be useful in the development of broad-spectrum host-oriented therapeutics and vaccines.
Protein kinases and phosphatases regulate a range of cellular responses to external and internal stimuli, including cell proliferation, metabolism and apoptosis.
Aberrant kinase and/or phosphatase activities underlie many different types of pathological conditions from cancer to infectious diseases. Protein kinases have been extensively investigated as targets for drug discovery. In addition, phosphatases are now being recognized as important regulators of many biological processes. In particular, there is an increasing interest in protein tyrosine phosphatases (PTPs) as drug targets (3) (4) (5) (6) (7) (8) , because immune cells express a remarkably high proportion of the 107 PTP genes in the human genome (9) and also due to the growing number of human diseases discovered to be associated with PTP abnormalities (9) (10) (11) . The involvement of cellular and bacterial PTPs during intracellular microbial pathogenesis has been a topic of significant interest (2, 12, 13) . The bacterial PTP YopH, secreted by Yersinia pestis interferes with the host adhesion regulated signaling pathway via dephosphorylation of selective tyrosine phosphorylated proteins (14) . Activation of host PTPs following infection with bacteria or their virulence factors has been demonstrated for a diverse group of microorganisms such as Mycobacterium tuberculosis and Leishmania donovani (13) . Specific mechanistic models of how PTPs contribute to the development of infection and disease progression by highly lethal organisms still remain unclear.
Bacillus anthracis, a gram positive sporeforming bacterium is the etiologic agent of anthrax. The lethal toxin (LT) produced by B. anthracis can cleave host cell mitogen activated protein kinase kinases (MAPKK), thereby affecting the immune response and the host's ability to fight the infection (15, 16) . Macrophages are the primary targets of anthrax LT. However, macrophages from only certain strains of mice are susceptible to LT mediated cell death (17, 18) . To date, there is no direct relation between MAPKK cleavage and LT induced macrophage cell death, as LT resistant macrophages exhibit MAPKK cleavage (19) (20) (21) . This suggests that other cellular target/s may play a role in anthrax pathogenesis.
Previously, using a chemical genetic approach, we identified a class of Cdc25 inhibitors that protected macrophages from cell death induced by anthrax LT (22) . Although Cdc25 was not the cellular target, induction of anti-apoptotic responses by the compounds, via either the MAPK dependent or -independent pathways, was responsible for the protective phenotype.
In the present study, we investigated if the previously identified phosphatase inhibitors (22) and their analogs produced any phenotypic changes in the B. anthracis infection model. Two compounds that previously protected LT treated macrophages (22) also protect B. anthracis infected macrophages.. Subsequent in vitro phosphatase profiling studies identified CD45, a previously unknown target of one of the small molecules, as the most sensitive enzyme to the inhibitor. We then investigated the effect of CD45 reduction in anthrax pathogenesis, both in cells and in vivo, by using antisense phosphorodiamidate morpholino oligomers and mice engineered to express reduced levels of CD45.
EXPERIMENTAL PROCEDURES
Heterozygous and Transgenic mice -All mice in this study are of the C57BL/6 genetic background. C57BL/6 (CD45 100% ) wild type mice and exon-9 disrupted CD45 knockout mice were obtained from Jackson Laboratories (Bar Harbor, Maine). The heterozygous CD45 62% mice have one exon 9 knockout allele and one wild type allele. Transgenic mice containing a point mutation (C817S) in the membrane proximal phosphatase domain of the CD45 minigene were produced using a CD45 minigene construct containing cDNA for exons 1b-3, the genomic sequence from exon 3 to exon 9, which includes the variably spliced exons and surrounding introns, and cDNA from exon 9 through the polyadenylation signal region in exon 33, as described previously (23, 24) . The minigene expresses CD45 in transgenic mice in the same leukocyte restricted manner and with the same isoform regulation in leukocyte subsets as the endogenous gene (24) . The C817S mutation eliminates the catalytic site of the membrane proximal PTPase domain and has been shown to abolish CD45 PTPase activity in vitro (25) , which has been confirmed in ex vivo studies (manuscript in preparation). The CSV10 transgenic founder generated using the C817S mutant minigene was bred onto the exon-9 disrupted CD45 knockout strain for seven generations to place the transgene on the CD45 knockout and C57BL/6 backgrounds.
The CD45 cell surface expression levels of heterozygous and CSV10+/-mice were determined with flow cytometry by comparison of the mean fluorescence intensities of the lymphocyte populations to those of CD45 100% wild type and CD45 0% knockout mice (24) . The expression level of CSV10 transgenic mice containing one copy of the transgene insertion locus (CSV10+/-) is 62-65%, a level similar to that expressed by CD45 62% heterozygous mice. Chemical library -A focused library of known phosphatase inhibitors and related napthoquinoneand dione-containing derivatives was used for screening (supplementary Table 1 ). These compounds were obtained from the NCI Open Chemical Repository and their structures are available on the following web site: http://pubchem.ncbi.nlm.nih.gov/. The CD45 inhibitor (N-(9,10-Dioxo-9,10-dihydrophenanthren-2-yl)-2,2-dimethyl propionamide) was obtained from Calbiochem, while its related analogs (Phenanthrene-9,10 dione) and (4-NitroPhenanthrene-9,10 dione) were obtained from Sigma. PMO design and synthesis -The sequence of the CD45 PMO targeting the translational start site is 5' CCACAAACCCATGGTCATATC 3'. The scrambled PMO (5' CGGACACACAAAAAGAAAGAAG 3') was used as a nonbacterial negative control. For efficient delivery of PMOs into cells, an Arg-rich peptide [CH 3 CONH-(RAhxR) 4 -Ahx-βAla, designated P007; in which R stands for arginine, Ahx stands for 6-aminohexanoic acid, and βAla stands for beta-alanine] was covalently conjugated to the 5′ end of the PMOs through a noncleavable piperazine linker. The methods for the syntheses of PMOs, the conjugation of P007, and the purification and analyses of P007-PMOs have all been described previously (26, 27) . Phosphatase activity assay -Protein phosphatases were purchased from Upstate (Lake Placid, NY). A generic substrate, DiFMUP (6,8-difluoro-4-methylumbelliferyl phosphate) was purchased from Invitrogen (Carlsbad, CA). All assays were performed in 50 mM HEPES containing 1 mM DTT and 0.1% BSA, pH 7.4 with the following modifications or additions: SHP1, PTPMEG2, and PTPβ (10 mM MgCl 2 ); PP1α, PP1β and PP2A (10 mM MnCl 2 ); HePTP, VHR, CD45, TC-PTP, SHP-2, LMPTPA (pH 4.5) and LMPTPB (pH 4.5); PTPMEG-1 (4.8 mM MgCl 2 B and 3.2 mM MnCl 2 ); PTP-1B (25 mM HEPES, 50 mM NaCl, 5 mM DTT and 2.5 mM EDTA). Compound (10 µM) was added to 15 µl enzyme and incubated for 10 min followed by 10 µL DiFMUP at a final concentration of 100 µM. The 384 well plate was incubated at room temperature for 60 min and then read in an Analyst (MDC using excitation 360 nm; emission 450 nm). The effect of the compound was compared to control wells containing DMSO (1%). The different phosphatase enzyme characteristics and their concentrations used in this assay have been detailed in supplementary Table  2 .
Cdc25B phosphatase activity was measured as described previously (22, 28) .
Briefly, assay cocktail containing 30 mM Tris (pH.8.0), 75 mM NaCl, 1 mM EDTA, 0.033% BSA, I mM DTT, 40 µM of 3-O-methyl fluorescein phosphate (OMFP) and 0.7 µg/ml of His-Cdc25B catalytic domain (a kind gift from Dr. John Lazo, University of Pittsburgh), was incubated with NSC 95397 in DMSO or DMSO (control) for 1 hour at room temperature. The reaction was quenched by adding 100 mM NaOH and increase in fluorescence was measured at an excitation wavelength of 485 nm and emission wavelength of 530 nm.
To measure CD45 phosphatase activity in protein lysates, equal concentrations of total protein (200 µg) from untreated or PMO-treated macrophages (8 µM, 72 hr treatment) were first precleared with protein G sepharose beads and then immunoprecipitated overnight with either the nonspecific monoclonal antibody or CD45 specific (clone 30-F11, BD Biosciences) antibody in the presence of protein G beads. After washing, the beads were incubated with 100 µM of DiFMUP substrate in 100 µl of assay buffer for 1 hr. Supernatant was transferred into 96-well plates and fluorescence intensity was measured at excitation 358 nm and emission 455 nm. The experiments were repeated independently at least three times. The results are given as averages with standard deviations. Flow cytometry -Antibodies used for FACS analysis were purchased from BD Pharmingen (San Diego, CA), unless otherwise noted. o C, bacterial growth was inhibited by the addition of the antibiotics Penicillin (100 IU) and Streptomycin (100 µg/mL). To determine cell viability sytox green nucleic acid stain (1 µM, Molecular probes) which is impermeant to live cells was added and incubated for 15 min at 37 o C. The cells were centrifuged at 2000 rpm for 2 min and then washed two times with complete medium containing antibiotics. The cells were fixed with 1% formaldehyde for 15 min and then analyzed by flow cytometry.
To test the effects of CD45 knock-down on cell viability following B. anthracis infection, J774A.1 cells (6x10 5 ) were either left untreated or treated with CD45 or SC PMOs. After 72 hr, cells were harvested and infected with the Sterne spores (5 MOI). After 4 hr incubation at 37 o C, cell viability was measured by the uptake of sytox green dye (as described above). Immunoblot analysis -J774A.1 cells (~1x10 6 ) seeded in a 6 well plate were either left untreated or incubated with CD45 or scrambled PMO for 72 hr. Cells were harvested and lysed in buffer containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, and protease inhibitor cocktail (Sigma). The cell lysates were incubated for 30 min on ice and then centrifuged for 30 min at 14,000 rpm. Cell extracts (30 μg) were electrophoresed on SDS-PAGE and then subjected to western blotting. A CD45 specific mouse monoclonal antibody (clone 69, BD Pharmingen) was used to detect the immunoreactive proteins that were visualized by Enhanced Chemiluminescence (ECL).
To determine the MEK cleavage pattern, J774A.1 cells were treated with the CD45 or scrambled PMOs (8 µM) for 72 hr. Cells were harvested and then treated with anthrax lethal toxin (100 ng/ml of Protective antigen (PA 83 ) and 20 ng/ml of LF) or infected with B. anthracis Sterne spores (5 MOI). After a 4 hr incubation time, cells were washed with phosphate buffered saline (PBS), lysed and electrophoresed as described above. Western blots were probed with MEK1"NT" antibody (Upstate Biotechnology) or GAPDH for uniform protein loading and visualized by ECL. Animal studies -Eight to ten week old mice were used in this study and included both males and females.
For 0% and CSV10+/-mice were challenged via intraperitoneal (ip) route with ~300 cfu of Ames strain of B. anthracis. The mice were monitored for one month post challenge.
To test the efficacy of PMOs in vivo, BALB/c mice (6-8 weeks old, n=6) were pretreated via subcutaneous (sc) route with PBS or CD45 PMO or scrambled PMO for 2 days (days -2, -1). On the third day (day 0), the mice were treated with the PMOs and infected via ip route with Ames spores (~750 CFU). An additional PBS or PMO treatment was given the day after challenge (day 1). Non-tagged PMOs were used for in vivo studies and injected at a dose of 100 mg/kg/day. The mice were monitored for one month post challenge. B. anthracis Ames spores from the same batch were used for all the in vivo mice studies described in figures 4 and 5.
To determine the humoral responses, CD45 100% and CD45 62% mice were vaccinated two times at two week intervals via intraperitoneal injection with 100 µl of anthrax vaccine adsorbed (AVA) mixed with 10 µg of QS-21 diluted in endotoxin-free PBS. After 35 days mice were euthanized, blood collected and protective antigen (PA) specific antibodies were measured by ELISA.
All research was conducted under an approved protocol and in compliance with the Animal Welfare Act and other federal statutes and regulations related to animals and experiments involving animals and adhered to principles stated in the "Guide for the Care and Use of Laboratory Animals", National Research Council 1996. The facility where this research was conducted is fully accredited by the Association for Assessment and Accreditation of laboratory Animal Care International. Phagocytosis and spore viability -To enumerate the spores ingested by macrophages, thioglycolate elicited peritoneal macrophages from CD45 100%, 62% and 0% mice were infected with 5 MOI of GFP-Sterne spores and plate centrifuged to synchronize the infection. After 30 min, nonpermeabilized cells were incubated with a mix of antibodies specific for B. anthracis spore exosporium (to label extracellular spores) and bacillus polysaccharide (to label extracellular vegetative bacilli) (kindly provided by T. Abshire and J. Ezzel, USAMRIID), followed by a secondary incubation with antibody conjugated to Alexa-594 nm fluorophore. This method labels only those spores adhered to the outside surface of the macrophages. After fixation with formaldehyde, cells were stained with Hoechst dyes and images from nine sites/well were collected and analyzed using the Discovery-1 high-content screening system (Molecular devices, Downington, PA). Images were analyzed using the cell health module of MataXpress imaging analysis software. Total cell count was based on the number of Hoechst-stained cell nuclei, while co-localization of red (anti-spore and anti-bacterial antibody) and green (GFP-Sterne spores) fluorescence was scored as spores being on the outside of the cell and with green only fluorescence being scored as ingested spores.
To measure spore viability, thioglycolate elicited peritoneal macrophages purified by plastic adherence were infected with Sterne spores at an MOI of 5. After 30 min, cell pellets collected by centrifugation were lysed in sterile water, serially diluted and aliquots were plated onto solid LB agar medium plates, which were then incubated at 37 o C for 16 hours. Colony forming units (CFU) were counted and data are represented as CFU/ml. Experiments were performed in duplicate and repeated three independent times. Table 1) were screened in infected macrophages. J774A.1 macrophages pretreated with DMSO control or compounds (10 µM) for one hour were infected with B. anthracis Sterne spores (5 MOI). After 4 hr, cell viability was measured by the uptake of sytox green dye using flow cytometry. Two compounds NSC 95397 and NSC 270012 were found to protect B. anthracis infected macrophages from cell death (Fig. 1A) . These two compounds were previously shown to protect macrophages from anthrax LT mediated cell death (22) .
To determine if increased compound concentration would result in greater cell viability, a dose response study using NSC 95397 was performed (supplementary Fig. 1) . The results show that the protective efficacy was limited to a narrow dose range of the compound. At concentrations greater than 10 µM, cellular toxicity was observed. Further characterization studies showed that the two most potent compounds, NSC 95397 and NSC 270012 (Fig.  1B) , did not inhibit: 1) the growth of B. anthracis spores (Fig. 1C) , 2) the enzymatic activity of anthrax lethal factor (LF) (22) , or 3) cellular proteasome activity (22) , a host component exploited by anthrax lethal toxin (LT) to kill susceptible macrophages (29) .
Previously, enzymatic assays showed that NSC 95397 inhibited Cdc25, a family of dual specificity phosphatases that function as important regulators of cell cycle progression (28) . Furthermore, NSC 95397 was shown to block G2/M transition in murine and human carcinoma cells (28) . However, in J774A.1 macrophages NSC 95397 did not seem to inhibit the cell cycle progression at G2/M phase (supplementary Fig. 2) , suggesting that Cdc25 phosphatases may not be the target of this compound, and hence not involved in protection from B. anthracis infection. To determine the involvement of any other phosphatases, NSC 95397 was screened for inhibitory activity against a panel of sixteen different phosphatases (Fig. 1D and supplementary  Table 2 ), which represents a fraction of the 107 known PTP genes in the human genome. NSC 95397 inhibited several phosphatases to varying extents, implicating these enzymes as potential cellular targets mediating protection against B. anthracis infection. However, maximum inhibition was observed for CD45 and dose response study showed that NSC 95397 has an IC 50 value of 3.0 µM for this enzyme (supplementary fig. 3 ). The majority of the phosphatases tested in this panel belong to the class of protein tyrosine phosphatases (SHP-1, SHP-2, PTP1B, CD45, TCPTP, LMPTP-A, LMPTP-B, MEG1, MEG2, HePTP, PTPbeta), three belong to the class of serine/threonine phosphatases (PP1alpha, PP1beta and PP2A) and two are dual specificity phosphatases (VHR, Cdc25B).
Small molecule CD45 inhibitor and its analogs protect B. anthracis infected macrophages. CD45 is abundantly expressed in all nucleated hematopoietic cells and is a well-known regulator of T and B cell antigen-receptor (TCR and BCR) signaling via the dephosphorylation of the Src-family kinases (SFKs) (30) (31) (32) . Furthermore, CD45 triggers cytokine production via receptors on NK (33, 34) , mast (35) , neutrophil (36) and dendritic cells (DCs) (37, 38) . However, very little is known about the role of CD45 in macrophages during lethal microbial infection. To determine if the protective effect of NSC 95397 resulted from reduced CD45 function, a known CD45 inhibitor (39) and its analogs (Table 1) were first tested using an in vitro CD45 enzymatic activity assay. The CD45 inhibitor (N-(9,10-Dioxo-9,10-dihydro-phenanthren-2-yl)-2,2-dimethyl propionamide) and its analog (Phenanthrene-9,10 dione) were both potent inhibitors of CD45 in vitro with IC 50 values of 0.4 µM and 0.3 µM respectively (Table 1) . These compounds were then tested in a cell based B. anthracis infection assay. As shown in Fig. 2 , an increase in cellular protection was observed at a higher concentration (10 µM) of the known CD45 inhibitor (Calbiochem 540215). An intermediate peak observed in the histogram at this high concentration (10 µM) represents a cell population that may have taken up the sytox green dye and hence reduced viability. The compound 156507, a structural analog of the known CD45 inhibitor is a better inhibitor of CD45 enzymatic activity but it did not show increased protection on macrophages. This may presumably be due to poor uptake properties.
CD45 knockdown using antisense phosphorodiamidate morpholino oligomer (PMO).
To further investigate the effect of reduced CD45 activity in B. anthracis infection, an optimized antisense phosphorodiamidate morpholino oligomer (PMO) targeting the translational start site of CD45 mRNA was tested. A timedependent study showed a maximum knock-down of CD45 expression in macrophages was achieved within 48-72 hr of PMO treatment, while a scrambled control had no effect on CD45 expression (Fig. 3A) . Dose escalation studies showed reduced CD45 expression with increasing PMO concentration (supplementary Fig. 4) , and that concentrations up to 9 µM were not toxic to cells. Knock-down of CD45 levels by the targeted PMO was further confirmed by Western blotting (Fig. 3B) , and reduction in CD45 phosphatase activity was measured using DiFMUP as substrate in a fluorescent based assay (Fig. 3C) .
CD45 knockdown in vitro protects macrophages and in vivo protects mice from B. anthracis induced death.
To determine if reduced CD45 expression could reduce B. anthracis induced death, PMO-treated macrophages were infected with B. anthracis spores and cell viability was determined by measuring the uptake of the membrane impermeable sytox green dye using flow cytometry (Fig. 4A ). Cells treated with CD45 PMO showed increased viability at higher PMO concentrations (8 µM) compared to either untreated or scrambled PMO-treated controls. These findings indicated that the induction of macrophage cell death can be reduced substantially by a mechanism that involves a tyrosine phosphorylation dependent pathway.
The different MEK isoforms have been shown to be the prime targets for anthrax LT proteolytic activity (16, 40) . However the observed protection (Fig. 4A ) did not correlate with MEK cleavage patterns, as cells treated with CD45 PMO and then infected with spores or treated externally with LT, exhibited MEK cleavage similar to control cells (Fig. 4B) . Furthermore, reduced CD45 expression by PMO treatment did not prevent LT mediated cell death (Fig. 4C ). This suggests, that the relevant CD45 dependent pathway may not signal through MEK. To date, the direct relationship between MEK cleavage and macrophage susceptibility has not been established, as macrophages that are resistant to LT induced cytolysis do exhibit MEK cleavage (19) .
To investigate the role of CD45 knock-down in an in vivo mouse model, mice (n=6) were pretreated via subcutaneous (sc) route with either PBS control, scrambled PMO or CD45 PMO for 2 days. On day 3, the mice were challenged with lethal Ames spores and treated with the PMOs. An additional treatment with the PMOs was administered one day following challenge and survival of mice monitored for 30 days. CD45 PMO treated mice that were challenged with Ames showed an increase in survival rate (50%) compared to scrambled PMO or PBS controls which succumbed to the pathogen (Fig. 4D) . A statistically significant increase (P=0.0026, using the Kaplan Meier survivor analysis log rank test) in the survival curves between the wild type (PBS controls) and each of the treatment groups was observed (supplementary Fig. 5 ) were protected with a survival rate of 65% (Fig. 5A) .
A statistically significant difference (p=0.0050) in the survival curves between the CD45 100% and CD45 62 % was observed using the Kaplan Meier survival analysis log rank test (supplementary Fig. 6 ). Subsequent studies with transgenic mice expressing intermediate CD45 levels (CD45 62% , F+/+) showed a survival rate similar to the heterozygous CD45 62% mice following challenge with Ames B. anthracis (supplementary Figure 7) . CD45 62% mice that survived 48 hr (Fig. 5B right panel) or one month (data not shown) after B. anthracis challenge showed no bacilli in the spleen (Fig. 5B right  panel) , lymph nodes or lungs (data not shown), as observed by immunohistochemical staining with anti-capsule antibody. In contrast, spleen from moribund CD45 100% mice showed a heavy bacterial burden in the red pulp (RP) areas with fewer bacilli appearing in cells associated with the marginal zone (MZ) and no visible bacilli in periarteriolar lymphoid sheaths (PALS) (Fig. 5B,  left panel) .
Our in vivo data resulting from these genetically engineered mice suggests that intermediate levels of functionally active CD45 enzyme generate a robust protective immunity that allows the immune cells to respond to B. anthracis infection.
Functional consequences of reduced CD45 expression.
To determine if reduced CD45 expression affected the humoral responses, CD45 62% and CD45 100% mice with reduced CD45 expression were vaccinated with anthrax vaccine adsorbed (AVA), and antibody titers were measured after 35 days. The CD45 62% mice generated robust antibody responses similar to the wild type controls suggesting that reduction in CD45 levels had no effect on humoral responses (Fig. 6A) . To investigate if reduced CD45 levels disrupted the biological functions of immune cells, the phagocytic and killing properties of peritoneal macrophages were measured. Macrophages harvested from the CD45 62% or CD45 0% mice possessed the ability to internalize the spores (Fig.  6B ) and kill the bacteria (Fig. 6C) as efficiently as those from CD45 100% mice. Prior studies have shown that macrophages from inbred strain of mice vary in their sensitivity to LT induced cell death (19, 20) . Macrophages from C57BL/6 mice are resistant to LT induced lysis. However activated macrophages from these mice strain can undergo apoptosis following LT treatment (40, 41 (Fig.  7B) . In blood (Fig. 7C) 
DISCUSSION
Several different approaches and experimental mouse models have been developed to investigate anthrax pathogenesis, B. anthracis virulence mechanism, critical cellular players, host immune response to the pathogen and potential therapeutic targets (43) (44) (45) (46) . To date, host proteins such as anthrax toxin receptors (ANTXR1 and ANTXR2) (47) and low density lipoprotein receptor-related protein 6 (LRP6) (48) have been considered as potential therapeutic targets against anthrax toxin mediated death. However, the role of LRP6 in anthrax toxin mediated lethality is still not clear (49) and the in vivo protective efficacy of the polyvalent inhibitors developed against the anthrax host receptors has been tested only in the rat lethal toxin model (47) . Antibacterial effects of host endoribonuclease RNase-L (50), interferon-inducible host chemokines (51) and caspase-1 mediated interleukin-1β expression (52) have been implicated as important participants in the host defense in mice challenged with Sterne strain of B. anthracis. To date, the role of these critical host targets has not been demonstrated in the highly virulent Ames infection model. In a recent study by Walberg et al (53) , pretreatment of mice with interferon-β resulted in increased survival following challenge with Ames B. anthracis. However, our study is the first to demonstrate that reduced expression of a host protein can provide protection against the highly pathogenic Ames strain infection in vivo.
An important implication of this study is that small molecules identified by in vitro biochemical assays may exhibit off-target effects and hidden phenotypes owing to their ability to bind to multiple targets. Such off-targets effects may cause cellular toxicity, but more importantly prove useful for therapeutic intervention or serve as valuable research tools. Furthermore, if the therapeutic class of the compound is known, it could lead to the identification of unrecognized host targets. An unanticipated, hidden phenotype of our known Cdc25 inhibitor (NSC 95397) was its ability to protect macrophages from B. anthracis induced cell death. Structurally NSC 95397 contains an electrophillic naphthalene dione scaffold, which possesses the potential to engage in Michael type additions, and therefore, may reduce thiol groups of proteins indiscriminately. Despite this potential reactivity, studies by Lazo et al (28) have shown that this compound is a potent and selective inhibitor of Cdc25B compared with either the dual specificity phosphatase VHR or the protein tyrosine phosphatase PTP1B. Given these findings, the prospect of developing a highly specific, inhibitor analog of NSC 95397 has promise as modifications to the naphthalene-dione scaffold may result in greater specificity. For example, although the catalytic centers of phosphatases often contain a reactive thiol, the spatial disposition of amino acid side chains around this center may influence the steric accommodation of the ligand during the reduction. This could be the case with NSC 95397. Providing some support for this notion is the relative specificity that NSC 95397 demonstrated previously for Cdc25B (28) . Moreover, with respect to this investigation, NSC 95397 has demonstrated a greater inhibitory potency for CD45 relative to Cdc25B, and its lack of inhibitory activity for a number of other phosphatases (shown in Fig. 1D ) seems to warrant additional SAR studies with CD45 as the target. In light of the potential multi-targeted nature of NSC 95397 and to further investigate whether modulation of CD45 activity is associated with the observed protection to B. anthracis, studies utilizing antisense approaches and mice with reduced CD45 expression were conducted.
Our data suggest that regulated CD45 signaling via reduced CD45 expression levels and hence reduced protein tyrosine phosphatase activity provides protection during virulent Ames B. anthracis infection. The exclusive expression of CD45 by hematopoietic cells coupled with the natural role of these cells in host-pathogen interactions strongly suggest that cells of innate and/or adaptive immunity are responsible for the protective effect.
Indeed we find several properties of the immune cells being critically affected. The rapid protective response required for B. anthracis infections, within 2-3 days, predicts that early activation of innate immunity may be critical for survival of mice with reduced CD45 expression. The in vivo time course data suggest that the increased percentages of splenic and peripheral macrophages and granulocytes following B. anthracis infection in CD45 62% mice may trigger innate and T cell-mediated responses, resulting in bacterial clearance. Although the role of macrophages or T cells in pathogenesis of anthrax is not well established, recent studies have shown that macrophages (44) and even T cell (54) immune responses are critical in animal survival following B. anthracis infection. The robust protection elicited by intermediate levels of CD45 may possibly be a consequence of differential regulation of the regulatory phosphorylation sites (pTyr-505 and pTyr-394) of p56lck, a src-family kinase with a key role in T cell signaling (42, 55) . Thus, differential CD45 expression levels may control the sensitivity of the signaling pathway. Moreover, the observed protection is not an inherent condition of the genetic reduction of CD45 expression levels, as knockdown of CD45 by PMO in wild type mice resulted in a survival rate similar to the CD45 62% mice following infection with B. anthracis. However, the control and clearance of bacterial infections in CD45 62% mice is dependent on CD45 phosphatase activity, by guest on November 19, 2017 http://www.jbc.org/ Downloaded from as CSV10 mice with 62% CD45 expression but with no CD45 phosphatase activity, succumbed to the pathogen. The underlying mechanism of how reduced CD45 expression modulates immune cell signaling, which in turn controls the clearance of the pathogen is not yet fully understood and requires further investigation. The difference in survival of CD45 100% and CD45 62% mice is not due to Nalp1b allelic differences known to confer sensitivity or resistance of macrophages to anthrax LT in vitro (56) , since the C57BL/6 mice strain do not carry the Nalp 1b allele that confers susceptibility, yet are sensitive to B. anthracis-induced death. In confirmation, macrophages from the wild type C57BL/6 mice and the CD45 0% and CD45 62% mice used in this study are resistant to LT induced lysis (Supplementary Figure 8) .
It is important to note that B. anthracis spores and independently added LT appear to signal through at least partially divergent pathways, as our results demonstrate that reduced CD45 expression via PMO treatment protects macrophages following B. anthracis infection but direct addition of LT does not protect. In contrast, we have previously shown that NSC 95397 prevented MEK1 cleavage and inhibited LT induced apoptosis of macrophages (22) . These observed differences between NSC 95397 and the CD45 PMO studies could be due to the compound inhibiting multiple targets. Furthermore, reduced apoptosis was observed in macrophages derived from CD45 62% mice compared to the control CD45 100% mice, indicating that differential levels of CD45 may regulate apoptosis in B. anthracis infection.
To date, the functional role of CD45 has been studied in CD45 -/-cell lines, CD45 knockout mice and mice expressing single CD45 isoforms. Changes that result from only partial reduction in levels of all isoforms of CD45 in cell-based and whole animal models still need to be fully explored. Such changes would mimic conditions resulting from therapeutic administration of the PTPase inhibitors or antisense molecules. Our findings suggest that specific PTPs such as CD45 could be targeted for therapeutic intervention of infections by B. anthracis and possibly other infectious diseases. Furthermore, development of host-oriented adjunctive therapeutics would be effective against both the natural and engineered resistant forms of the bacteria. A reduction in CD45 protein levels was observed in cells treated with a higher concentration (8 µM) of CD45 PMO compared to untreated or SC PMO. As a control for uniform protein loading, the bottom half of the blot was probed with GAPDH antibody. (C) CD45 was immunoprecipitated from protein lysates prepared from macrophages that were either untreated (Un) or treated with CD45 or SC PMOs and phosphatase activity was measured using DiFMUP substrate. A reduction in CD45 phosphatase activity was observed in cells treated with CD45 PMO, but not with SC. Data from three independent experiments is averaged ± s.d. . After 4 hr cell viability was measured using a MTT assay. The data represent the averages ± SD for two independent experiments done in triplicates (D) CD45 PMO treatment protects mice. BALB/c mice were treated subcutaneously with PBS control (WT, n=6) or CD45 PMO (n=6, 100 mg/kg/injection) or SC PMO (n=6, 100 mg/kg/injection) on days -2, -1, 0 and +1. On day 0, mice were infected intraperitoneally with Ames B. anthracis spores (~750 CFU). A 50% survival rate was observed in the CD45 PMO treated mice. 62% and CD45 0% mice were infected with Sterne spores for 30 min, cells were lysed and the entire mix was plated and CFU/ml were determined. The data represent averages from three independent experiments ± standard deviation (s.d.). (D) Thioglycolate elicited peritoneal macrophages from CD45 100% or CD45 62% mice were either left untreated or infected with Sterne spores (10 MOI) or treated with staurosporine (2 µM) for 6 hr and then examined for apoptosis using an Apo-One homogenous Caspase-3/7 kit. The fold change in apoptosis represents the ratio of treated to untreated cells. The data represents averages of three independent experiments ± standard error (s.e). (E) Thioglycolate elicited peritoneal macrophages harvested from C57BL/6 mice were either not treated or treated with indicated concentrations of the compound NSC 95397 or staurosporine (2 µM) as positive control and then infected with Sterne B. anthracis spores. After 6 hours, apoptosis was measured using the Apo-One Homogeneous Caspase 3/7 kit. Table 1 by guest on November 19, 2017 http://www.jbc.org/ Downloaded from
